<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124552</url>
  </required_header>
  <id_info>
    <org_study_id>RT001-CL017LCL</org_study_id>
    <nct_id>NCT01124552</nct_id>
  </id_info>
  <brief_title>A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, 4-Arm, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revance Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revance Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if an investigational drug, called RT001 Topical
      Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called
      lateral canthal lines, also known as crow's feet wrinkles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RT001, a new drug, may be effective for the temporary improvement in the appearance of
      moderate to severe lateral canthal lines (crow's feet wrinkles) in adults. In this study,
      researchers want to find out if RT001 is more effective than three comparator groups by
      examining the effect on the improvement of crow's feet by both the patient and physician.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject improvement based in investigator assessment</measure>
    <time_frame>Week 4</time_frame>
    <description>The number of subjects who show improvement based on the investigator global assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Improvement Based on investigator and patient assessments</measure>
    <time_frame>Week 4</time_frame>
    <description>The number of subjects who show improvement based on the investigator global and patient assessments</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Lateral Canthal Lines</condition>
  <condition>Crow's Feet</condition>
  <condition>Facial Wrinkles</condition>
  <arm_group>
    <arm_group_label>RT001 Botulinum toxin Type A (Dose A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT001 (Botulinum toxin Type A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT001 Botulinum toxin type A (Dose B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT001 (Botulinum Toxin Type A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vehicle Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001 Botulinum toxin type A (Dose A)</intervention_name>
    <description>RT001 Botulinum Toxin Type A (Dose A)</description>
    <arm_group_label>RT001 Botulinum toxin Type A (Dose A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001 Botulinum Toxin Type A (Dose B)</intervention_name>
    <description>RT001 Botulinum Toxin Type A (Dose B)</description>
    <arm_group_label>RT001 Botulinum toxin type A (Dose B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle Control</description>
    <arm_group_label>Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Dose D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent including authorization to release health information

          -  Female or male, 18 to 65 years of age and in good general health

          -  Willing and able to follow study instructions and likely to complete all study
             requirements

          -  Moderate to severe lateral canthal lines (crow's feet wrinkles)

        Exclusion Criteria:

          -  Any neurological condition that may place the subject at increased risk with exposure
             to Botulinum Toxin Type A, including peripheral motor neuropathic diseases such as
             amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional
             disorders such as Lambert-Eaton syndrome and myasthenia gravis

          -  Muscle weakness or paralysis, particularly in the area receiving study treatment

          -  Active disease or irritation at the treatment areas including the eye and the skin

          -  Pregnant, nursing, or planning a pregnancy during the study; or is a women of child
             bearing potential (WOCBP) but is not willing to use an effective method of birth
             control

          -  Previous participation in a RT001 clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dermatology Research Institute, LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <disposition_first_submitted>June 13, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 13, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 27, 2011</disposition_first_posted>
  <last_update_submitted>December 24, 2013</last_update_submitted>
  <last_update_submitted_qc>December 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lateral Canthal Lines</keyword>
  <keyword>Crow's Feet Wrinkles</keyword>
  <keyword>Facial Wrinkles</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

